Curie, Aurore

Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine

Genetics and Neurodevelopmental DisordersGenetic Neurodegenerative Diseases

Cited by 609

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery

Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology Research

Cited by 336

Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis

Curie, A., Yang, K., Kirsch, I., Gollub, R. L., des Portes, V., Kaptchuk, T. J., & Jensen, K. B. (2015) · PLOS ONE

Pain Management and Placebo EffectDown syndrome and intellectual disability research

Cited by 43

Certainty of genuine treatment increases drug responses among intellectually disabled patients

Jensen, K. B., Kirsch, I., Pontén, M., Rosén, A., Yang, K., Gollub, R. L., des Portes, V., Kaptchuk, T. J., & Curie, A. (2017) · Neurology

Pain Management and Placebo EffectDown syndrome and intellectual disability research

Cited by 17

Placebo effects in children with autism spectrum disorder

Curie, A., Oberlander, T. F., & Jensen, K. B. (2023) · Developmental Medicine & Child Neurology

Pain Management and Placebo EffectAutism Spectrum Disorder Research

Cited by 16